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Background: Identification of ligand-protein binding interactions is a critical step in drug discovery. Experimental
screening of large chemical libraries, in spite of their specific role and importance in drug discovery, suffer from the
disadvantages of being random, time-consuming and expensive. To accelerate the process, traditional structure- or
ligand-based VLS approaches are combined with experimental high-throughput screening, HTS. Often a single
protein or, at most, a protein family is considered. Large scale VLS benchmarking across diverse protein families is
rarely done, and the reported success rate is very low. Here, we demonstrate the experimental HTS validation of a
novel VLS approach, FINDSITEcomb, across a diverse set of medically-relevant proteins.
Results: For eight different proteins belonging to different fold-classes and from diverse organisms, the top 1% of
FINDSITEcomb’s VLS predictions were tested, and depending on the protein target, 4%-47% of the predicted ligands
were shown to bind with μM or better affinities. In total, 47 small molecule binders were identified. Low nanomolar
(nM) binders for dihydrofolate reductase and protein tyrosine phosphatases (PTPs) and micromolar binders for the
other proteins were identified. Six novel molecules had cytotoxic activity (<10 μg/ml) against the HCT-116 colon
carcinoma cell line and one novel molecule had potent antibacterial activity.
Conclusions: We show that FINDSITEcomb is a promising new VLS approach that can assist drug discovery.
Keywords: Drug discovery, Virtual ligand screening (VLS), High-throughput screening (HTS), Differential scanning
fluorimetry (DSF), Ligand homology modelingBackground
Traditional experimental approaches to drug discovery
rely on two different strategies [1]. The first selects a re-
liable therapeutic target that might be essential for an
organism’s or cell’s survival, and then, using chemical li-
brary screening, potential leads that bind to and modu-
late the activity of the target in vitro and subsequently,
in vivo, are identified. The second approach tests small
molecules on animal disease models or cell cultures
(called phenotypic screening), and once activity is
gleaned, the protein target is experimentally identified
by target deconvolution [2]. Both approaches have con-
tributed to the discovery of new drugs despite suffering
from substantial disadvantages of high cost and time.* Correspondence: skolnick@gatech.edu
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distribution, and reproduction in any mediumFragment-based drug discovery approaches have recently
gained prominence as a distinct and complementary ap-
proach to drug discovery [3]. Integration of a robust
VLS methodology with experimental HTS approaches
constitutes one of the many methods that might acceler-
ate the drug discovery process [4].
Despite its current limitations, VLS may be employed
as a possible first step in drug discovery [5]. It not only
aids in the selection of an appropriate protein target but
also narrows down the chemical space that is experi-
mentally screened to arrive at significant protein-ligand
interactions. In practice, both ligand- and structure-
based VLS approaches [6] have been used. The principal
disadvantage of a ligand-based approach is the need for
a priori knowledge of a set of ligands known to bind to
the target [7]. Structure-based approaches require a
high-resolution structure of the target; this situationntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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proteome [8]. To overcome these limitations, ligand
homology modeling (LHM) was developed to predict li-
gands that bind to the protein target [9-11]. LHM relies
on the fact that evolutionarily distant proteins share
functional overlap and their ligand-binding information
provides diverse bound ligands that can be employed in
a general VLS approach. Thus, it does not suffer from
the limitations of quantitative structure-activity relation-
ship (QSAR)-based approaches. In large scale bench-
marking, the FINDSITEcomb LHM approach exhibited
significant performance advantages over traditional ap-
proaches in terms of enrichment factor, speed, and in-
sensitivity as to whether experimental or predicted
protein structures are used [12]. However, experimental
assessment of the method, where blind predictions are
made and then experimentally tested, has not been done.
To ensure robustness, a diverse set of proteins and li-
gands must be examined, and the strengths and limita-
tions of the approach demonstrated.
A reliable and fast method that would test VLS predic-
tions and identify hits could help accelerate the drug-
discovery process. This could help alleviate the inherent
complexity of treating diseases due to cross-reactivity and
could address the rapid evolution of resistance to available
drugs by pathogenic microbes. We have resorted to the
thermal shift assay methodology to assess the predictions
from VLS [13]. The methodology is an inexpensive way to
assess the binding of small-molecules by the stability they
confer on thermal denaturation of the protein target of
interest. Upon thermal denaturation, the hydrophobicity
of proteins increases, leading to an increase in fluores-
cence of an extrinsic fluorophore reporter dye. This
method is amenable to miniaturization and can screen
hundreds of molecules simultaneously for their ability to
bind to the protein target of interest.
Recognizing the importance of these issues, in the
present paper, to assess if FINDSITEcomb [12] can improve
VLS, we selected an assortment of medically-relevant pro-
teins with differing fold-architectures from diverse organ-
isms including the causative agents of human and primate
malaria, Plasmodium falciparum and Plasmodium know-
lesi, an opportunistic pathogen Escherichia coli, and pro-
teins implicated in mammalian disorders (from Homo
sapiens and Rattus norvegicus). For these proteins, top
ranked ligands predicted by FINDSITEcomb are experi-
mentally assessed for binding by thermal-melt assays.
After validating the small molecule binding predictions,
we tested their physiological function by their ability to kill
bacteria such as multi-drug resistant E. coli (MDREC),
methicillin-resistant Staphylococcus aureus (MRSA),
Vancomycin-resistant Enterococcus faecium (VREF), and
their cytotoxic activity using HCT-116 colon carcinoma
tumor cell line. The encouraging experimental resultsfor both binding and physiological activity show that
FINDSITEcomb is an effective VLS tool.
Results
The section summarizes the results from FINDSITEcomb’s
VLS predictions on eight different proteins and their val-
idation by the thermal shift assay methodology.
Prior to assessing the VLS results on the eight protein
test set, the thermal shift methodology was validated on
three proteins having known binding and nonbinding li-
gands. Only cognate protein-ligand pairs showed shifts
in the transition mid-point of thermal melt curves, Tm,
while non-cognate ligands displayed no such shifts
(Additional file 1: Figure S1 and SI).
We next applied the methodology, as shown in Figure 1,
in benchmark mode to eight diverse proteins, viz.,
FINDSITEcomb only considered template proteins whose
sequence identities to the target was <30%. Typically on
the order of 50 ligands per protein gave interpretable ther-
mal shift curves. Of these, the experiments identified a
total of 47 small-molecule/protein binding interactions
with μM or better affinities. Ten ligands with apparent
nM binding affinities (less than 1 μM) were identified
for dihydrofolate reductase from E. coli and the two
mammalian protein tyrosine phosphatases (PTPs).
Except for a small fraction of known inhibitors, which
further validated the methodology, most are novel. The
prediction percentage success rate ranged from 3.9%
of ligands tested for the P. falciparum ubiquitin-
conjugating enzyme to almost 47% for dihydrofolate
reductase from E. coli (Table 1). This is a major advance-
ment over previously reported success rates [14]. The
small-molecules that displayed biological activity had low
μM or nM affinities in the in vitro thermal shift assay
(Table 2; Additional file 1: Tables S3-S5). This supports
the conjecture that their in vivo biological activity might
result from binding of the small-molecule with the
intended target protein. A more detailed summary of the
results is presented below.
E. coli dihydrofolate reductase (DHFR)
In silico screening of E. coli DHFR was carried out with
FINDSITEcomb in benchmarking mode (Additional file 1:
Table S2A). The top 1% of predictions, with 83 small-
molecules, was assessed for binding (Table 1). Fifteen
ligands, representing 47% of interpretable curves, showed
binding (Figure 1 and Table 1). Of these 15 hits, represent-
ing μM or better binders, six were previously reported
inhibitors of DHFRs from various organisms [15-19].
Among these known binding molecules, methotrexate
(NSC740) showed the maximum thermal shift of ~30°C
followed by 7H-Pyrrolo(3,2-f) quinazoline-1, 3-diamine
(NSC339578) [15], methylbezoprim (NSC382035) [16],
pralatrexate (NSC754230) [17], pemetrexed (NSC698037)
Figure 1 Flowchart of the overall approach and the thermal shift assay results. The first panel shows the in silico approach to predicting
protein-small molecule interactions. All predictions were in benchmarking mode with a 30% template SID cutoff and the top 1% of the hits tested
using thermal-shift assays. The second panel shows a representative fraction of the thermal melt curves that showed positive shifts for the tested
proteins. The numbers are the NSC notation that identifies each small-molecule. DHFR is E. coli dihydrofolate reductase, 1000001 is a PTP from
R. norvegicus, 1000006 is a PTP from H. sapiens, TrpRS is tryptophanyl tRNA synthetase from H. sapiens, UCE is ubiquitin-conjugating enzyme from
P. falciparum, NAP1 is nucleosome assembly protein 1 from P. knowlesi, TP2 is thioredoxin peroxidase 2 from P. falciparum and cDPK is the
wild-type cAMP-dependent protein kinase, catalytic subunit from H. sapiens. Small-molecule binders were tested for their antimicrobial & cytotoxic
activity against HCT-116 colon carcinoma cell line.
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(NSC61642) [19]. The approximate dissociation constant
(KD) of 62 nM for the enzyme-methotrexate (NSC740)complex matches reported literature values, which range
from 2 to 50 nM [20-22], within experimental error. Thus,
the thermal shift methodology provides an approximate
Table 1 Results from the thermal shift assays on eight proteins, ranked by best ligand binding*




No. of + vea
shifts/% +
vea shifts
Best hit (NSC) ΔTm (°C) KD (nM)
b Best hit structure
DHFR E. coli 83 32 15/46.9 309401 30.74 48.21
1000006 H. sapiens 59 43 6/13.9 133351 16.76 168.29
1000001 R. norvegicus 86 42 10/23.8 134137 12.30 406.0
TrpRS H. sapiens 94 12 5/41.7 750690 14.57 1277.51
UCE P. falciparum 80 51 2/03.9 93427 14.86 1376.09
TP2 P. falciparum 67 12 2/16.7 106231 5.7 40872.77
cDPK H. sapiens 80 19 3/15.8 27032 2.95 48538.90
NAP 1 P. knowlesi 82 54 4/07.4 36398 2.21 180135.58
1000001: Carboxy-terminus phosphatase domain of protein tyrosine phosphatase (2NV5), DHFR: Dihydrofolate reductase, UCE: Ubiquitin conjugating enzyme,
TrpRS: Tryptophanyl tRNA synthetase, TP2: Thioredoxin peroxidase 2, 1000006: catalytic domain of protein tyrosine phosphatase (2G59), cDPK: Catalytic subunit
of cAMP-dependent protein kinase, NAP1: Nucleosome assembly protein 1. aPositive thermal shift is indicated by the notation + ve. KD indicates dissociation
constants. bThe dissociation constant reported in this table are computed from the thermal shifts obtained. *The values reported in this table are experimental
in-vitro values.
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μM or nM KDs (Additional file 1: Table S3).
Nine small molecules are novel hits with no reported
binding to/activity against DHFRs. These molecules are
chemically diverse. The 15 different hits cluster into 10
distinct chemical classes based on a Tanimoto coefficient
(TC) cutoff of 0.7 (Additional file 1: Figure S2A).
NSC309401, the top novel hit in Table 1, showed appar-
ently better binding to E. coli DHFR than methotrexate
(KD of 48 nM and a thermal shift of almost 31 degrees)
and showed inhibition against several antibiotic-resistant
microbial strains (Table 2). It displayed a promising MIC
of 7.8 μg/mL against E. coli DH5α and a reasonableMIC (31.25 μg/mL) against MRSA and VREF. It also has
very potent activity against the HCT-116 colon carcin-
oma cell line with an IC-50 of 0.13 μg/mL (Table 2).
This corroborates findings from the NCI human tumor
cell line growth inhibition assay showing that this
molecule has activity (potency not revealed) against sev-
eral cancer cell lines including melanoma, prostrate,
colon, and breast (http://pubchem.ncbi.nlm.nih.gov, CID:
24198955, substance SID: 573494, compound name:
MLS002701801) [23]. We posit that its activity is at least
partly due to DHFR inhibition. Since NSC309401 inhibits
both prokaryotic and eukaryotic systems, it might be a
broad specificity antifolate. 2, 4-diaminoquinazolines and
Table 2 Antimicrobial and anticancer activities of a representative set of small-moleculesb
Proteina Identity (NSC) DH5α (MIC) MDREC (MIC) MRSA (MIC) VREF (MIC) HCT-116 (IC-50)
DHFR 309401 7.813 125 31.25 31.25 0.130
740* ND ND ND 500 0.048
339578* 62.5 250 31.25 31.25 6.11
382035* ND ND 31.25 31.25 0.182
754230* ND ND ND ND <<0.031
1000001 111552 NA NA NA NA 2.2
246131@ NA NA NA NA 0.024
30205 NA NA NA NA 0.146
88882 NA NA N A NA 4.44
106863 NA NA NA NA 14.5
1000006 92794 NA NA NA NA 9.78
TrpRS 750690¥ NA NA NA NA 1.11
88882 NA NA NA NA 4.44
37168 NA NA NA NA 1.34
*Reported inhibitors of DHFR independently picked up by our predictions and validated experimentally. @Small molecule with known anti-cancer properties
(valrubicin). ¥Small molecules with known anticancer properties (Sunitinib), MIC: Minimum inhibitory concentration required for 90% clearance, μg/mL units. ND:
No significant inhibition. NA: not applicable. DH5α: E. coli strain DH5α, MRSA: Methicillin-resistant S. aureus, MDREC: Multi-drug resistant E. coli, VREF: Vancomycin-resistant
E. faecium, HCT-116: Colon carcinoma cell line. IC-50: inhibitory concentration for 50% growth inhibition, μg/mL units. aFor additional details, see legend from Table 1. bThe
values reported in this table are experimental in-vitro values.
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example is trimetrexate) (Rosowsky, et al., 1995) but
their structures are different from NSC309401, a 7-[(4-
aminophenyl) methyl]-7Hpyrrolo [3, 2-f] quinazoline-1,
3-diamine, in that the latter compound has a novel tricyc-
lic heterocycle.
Another interesting small molecule, with no previously
reported binding to DHFR, was NSC80735, with a KD of
1.7 μM and a MIC of 10.9 μg/mL against HCT-116
(Additional file 1: Table S3). The other novel hits had af-
finities ranging from 6-75 μM; these hits represent po-
tential compounds that could be improved to increase
their medical significance vis-à-vis DHFR inhibition. A
single novel hit had a poor affinity of ~460 μM.
Protein tyrosine phosphatases (PTP)
The top 1% of VLS predictions (Additional file 1: Table
S2B and S2C), representing 86 and 59 molecules, were
tested on PTPs 1000001 and 1000006, respectively. Ten
molecules, 24% of the interpretable curves, showed posi-
tive shifts for PTP 1000001, and six molecules, 14%
of the interpretable curves, showed positive shifts for
PTP 1000006 (see Figure 1 and Table 1). However, it
should be noted here that a few of the reported mole-
cules have low Q values representing poor signal com-
pared to the thermal unfolding curve of the protein
alone (see Materials and Methods) (Additional file 1:
Table S4). All these compounds are novel hits, with no
reported binding to/activity against PTPs. At a TC cutoff
of 0.7, the 10 ligands showing experimental bindingto 1000001 clustered into eight different subgroups
(Additional file 1: Figure S2B), while the six ligands
showing experimental binding to 1000006 clustered into
four different subgroups (Additional file 1: Figure S2C).
This again demonstrates the diversity of ligands selected
by FINDSITEcomb. Next, 32 predictions ranked below
the top 1% from VLS were randomly selected and tested
experimentally on 1000001 and 1000006 to demonstrate
that the obtained hit rate for the top 1% was appreciably
better than the background. Convincingly, as inferred by
the lack of shift in Tm, none showed any binding.
Among the ten hits for 1000001, seven had μM
affinities, three had nM affinities with the compound
NSC134137 showing a maximal thermal shift of ~12°C.
This translates into an approximate KD of 406 nM
(Additional file 1: Table S4). Five of these compounds,
50% of the hits, displayed cytotoxic activity against
HCT116. Valrubicin (NSC246131), (a known anticancer
agent that intercalates with DNA [24]), was also shown
to bind to PTP1000001 with an approximate dissociation
constant of 1.5 μM. NSC246131 binding to PTP 100001
hints at promiscuity of this molecule. Three hits,
NSC111552, NSC30205 and NSC88882 also showed po-
tent cytotoxic activity (IC-50 of 2.20 μg/mL, 0.15 μg/mL
and 4.44 μg/mL, respectively), while NSC106863 showed
reasonable cytotoxic activity with an IC-50 of 14.5 μg/mL
against the HCT-116 colon carcinoma cell line (see Table 2;
Additional file 1: Table S4). We note that a single paper
reports the cytotoxic activity of NSC111552 derivatives
against cancer cell lines [25]. While there is no literature
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NSC88882, 9-aminoacridine-based compounds are known
to be cytotoxic towards cancer cell lines [26-33]. Thus, the
mode of action of NSC30205 could be similar [31]. We also
posit that the PTP human homologue is one of the targets
responsible for the cytotoxic activities of these molecules.
All six hits for 1000006 have apparent KDs that range
from 168 nM-271.5 μM (Additional file 1: Table S4).
The top hit was NSC133351 with an approximate dis-
sociation constant of 168.3 nM. NSC92794, with a KD of
161.9 μM, displayed reasonable cytotoxic activity with
an IC-50 value of 9.8 μg/mL against HCT-116 colon car-
cinoma cell line. None of the other hits of 1000006 dis-
played discernible cytotoxic activity. Since 1000001 and
1000006 are both PTPs and share substantial structural
similarity, there were instances where 1000001 binders
also bind 1000006 (Additional file 1: Table S6 and SI).
Ubiquitin-modifying enzyme (UCE)
For P. falciparum UCE, 80 molecules from the top 1% of
FINDSITEcomb predictions (Additional file 1: Table S2G),
were experimentally tested for binding (Table 1); only 51
gave interpretable thermal shift curves. Two molecules,
4% of the interpretable curves, showed binding (see
Figure 1 and Table 1). NSC93427 binds to UCE, with a
thermal shift of ~15°C that translates into an approximate
KD of 1.4 μM. Another compound, NSC50651, showed an
apparent KD of 197 μM (Additional file 1: Table S5).
Future studies to assess the inhibition of in vitro cultures
of P. falciparum by these small-molecules are needed to es-
tablish their utility as lead compounds for malaria treatment.
Tryptophanyl tRNA synthetase (TrpRS)
For TrpRS, 94 compounds from the top 1% of the VLS
(Additional file 1: Table S2D) were experimentally
screened (Table 1). Five, constituting 42% of the inter-
pretable curves, showed thermal shifts (see Figure 1 and
Table 1). The ligands clustered into three different sub-
groups (Additional file 1: Figure S2D) based on a TC
cutoff of 0.7. The most interesting small-molecule that
binds TrpRS was Sunitinib (NSC 750690) with an ap-
proximate KD of 1.3 μM and an IC-50 of 1.1 μg/mL for
HCT-116. The observed effect might be due to its inhib-
ition of multiple targets (receptor tyrosine kinases are
known Sunitinib targets [34]).
Two other small molecules, NSC88882 and NSC37168,
with ~KDs of 3.8 μM and 9.1 μM respectively, also
showed potent inhibition of HCT-116, with IC-50s of
4.44 μg/mL and 1.34 μg/mL, respectively (Table 2).
NSC88882 has been shown to possess activity in the
several bioassay trials undertaken by the NCI suggesting
high promiscuity across several protein targets (http://
pubchem.ncbi.nlm.nih.gov/, substance SID: 26665273,
CID: 68249) [31]. NSC37168 also binds multiple targetswithin different cell types [3,35]. However, none of
these reports suggest binding/inhibition of TrpRS. Other
compounds that bind TrpRS were NSC50690 and
NSC55152, having KDs of 7.7 μM and 39.6 μM, respect-
ively (Additional file 1: Table S4).
Thioredoxin peroxidase2 (TP2), cAMP-dependent protein
kinase (cDPK) and nucleosome assembly protein 1(NAP1)
TP2 from P. falciparum, the catalytic domain of the
cDPK from H. sapiens and NAP1 from P. knowlesi were
tested with moderate success. Their thermal melt assay
results are collated in Table 1 and Additional file 1:
Table S5, with additional VLS results summarized in
Additional file 1: Table S2F, S2E and S2H, respectively.
Experimental thermal melt curves are shown in Figure 1.
As can be seen in Additional file 1: Table S5, all these
small-molecules bind with μM affinities (ranging from
41 μM-371.5 μM), making a few of them potential can-
didates for further development.
Discussion
In this paper, we describe the large-scale experimental
validation of the FINDSITEcomb VLS methodology and
demonstrate that the approach is applicable to a wide
variety of proteins. In contrast, previous instances of
VLS coupled to experimental screening of ligands re-
ported in the literature mostly concentrate on either
a single enzyme or a single enzyme family [36-41].
FINDSITEcomb, being a hybrid of structure-based and
ligand-based VLS approaches, has many advantages: It
identifies a structurally diverse set of ligands as potential
hits, retains the speed of traditional ligand-based ap-
proaches, and removes the requirement of traditional
structure-based approaches that a high-resolution struc-
ture of the protein target of interest be solved. Thus,
~75% of a given proteome is accessible to this VLS meth-
odology. This affords the possibility not only of identifying
novel hits, but also for repurposing FDA approved drugs,
and concomitantly suggesting possible drug side effects.
Demonstration of the methodology on a diverse set of
proteins with differing folds suggests that the method is
a general and effective approach to discovering novel
protein-ligand binding interactions. The primary success
rates of 4%-47% are dramatic when compared to rates
reported in the literature. Since only a tiny fraction of
the protein/ligand binding predictions were assessed ex-
perimentally (20-50 of the top ranked predictions from
FINDSITEcomb), these success rates are even more sig-
nificant than the raw numbers would suggest. For in-
stance, in another study describing the HTS of a diverse
library of 50,000 small-molecules against E. coli DHFR,
the primary hit rate was 0.12% [14], whereas 47% of the
32 molecules predicted by FINDSITEcomb bind with μM
affinities or better. Indeed, the finding that many ligands
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three different proteins, novel nM binders were identi-
fied. Demonstration of antibacterial and cytotoxic activ-
ity by some of these compounds further suggests that
the present methodology is a promising approach to
identify novel hits and could help enrich the drug dis-
covery pipeline. However, we are aware that hits gener-
ated through thermal-shift methodology relying on an
extrinsic fluorophore will require additional validation.
Not only has a methodological advance been demon-
strated, but also the results hold possible medical signifi-
cance. We have identified several interesting hits that
might represent starting scaffolds for drug design for a
number of clinically important protein targets. For ex-
ample, DHFR, a pivotal enzyme in the nucleotide bio-
synthetic pathway in E. coli [42] evolves resistance to
available inhibitors by several mechanisms [43,44]. This
is a major problem because drug-resistant E. coli causes
the highest number of infections in hospitalized patients
[35]. Thus, there is an urgent need to identify novel po-
tent inhibitors of DHFR. In that regard, the current
study provides nine novel structurally diverse small-
molecule binders with apparent affinities ranging from
nM to μM that are interesting hits that could be devel-
oped as lead molecules for E. coli DHFR inhibition. By
assessing the potential of these ligands against a diverse
set of drug-resistant microbial strains and colon cancer
cells, we established the range of effectiveness of these
compounds. A potent antibacterial and 7 molecules with
cytotoxic effect against HCT-116 colon carcinoma cell
line were found. This information can be exploited in
designing species-specific inhibitors. Yet other examples
are the pathogens P. falciparum, which causes malignant
malaria in humans, and P. knowlesi, implicated in an
emergent form of malaria that can infect humans [45].
Rapid evolution of resistance to known antimalarials is a
major issue [46]. The present study yielded 8 hits to
three different enzymes that carry out critical processes
of ubiquitin-mediated post-translational modification
(UCE) [47], oxidative protection of the parasite during
its intraerythrocytic stages (TP2) [48] and histone trans-
port & chromatin assembly (NAP1) [49], in the patho-
gen. Finally, four distinct target proteins representing
members of three families, tRNA synthetases [50], phos-
phatases and kinases [51,52] implicated in diseases such
as cancer, were examined with 24 novel protein-ligand
binding interactions reported. Interestingly, these studies
also identified unanticipated binding interactions of
well-known drugs with alternative targets. Sunitinib, a
well-documented inhibitor of receptor tyrosine kinases
[34], binds to TrpRS with high-affinity. This reinforces
the belief that drug molecules, at least partly, work by
interfering with the function of multiple targets within
the cellular milieu. It is well known that developing anew drug is a time consuming and expensive process
that can take 12–15 years. Such off-target interactions
could be exploited towards repurposing available drugs
for alternative protein targets, thus reducing the cost
and time duration of drug-discovery.
Conclusions
In conclusion, we have demonstrated that FINDSITEcomb
is an automated, robust and rapid methodology that can
identify novel protein-ligand binding interactions that are
often in the nM range or better, and which, in combin-
ation with appropriate mechanistic studies and biological
activity assays can be a promising tool for lead identifica-
tion/drug discovery. The presented results show that pre-
dicted structures can be successfully used for virtual
ligand screening, and by exploiting the ideas of LHM, di-
verse novel small molecule binders can be identified even
when the closest template is distantly related to the
protein target of interest. Since medically relevant pro-
teins often have a large number of evolutionarily related
solved, holo protein structures that can serve as tem-
plates, they are a particularly good class of targets for
the present methodology. However, we note that the
methodology also works when there are few solved holo
templates structures in the PDB, e.g. for GPCRs [12].
Work is now in progress to extend and experimentally
validate the approach on a broader class of proteins
and small molecule ligands.
Methods
Details about reagents are provided in SI
Figure 2 shows the flowchart of FINDSITEcomb method-
ology [12] in combination with experimental validation
protocol. FINDSITEcomb is a composite approach con-
sisting of the improved FINDSITE-based approach [9]
FINDSITEfilt and the extended FINDSITE-based ap-
proach FINDSITEX [53]. In what follows, we detail the
two FINDSITE-based component approaches and their
benchmarking and prediction results.
FINDSITEfilt for ligand virtual screening using
experimental bound structures
The FINDSITEfilt flowchart is shown in Figure 3(A) and
consists mainly of three steps: (A) Finding a sub-set of pro-
tein template in the library of holo PDB structures (experi-
mental structures with bound ligands) that are putatively
evolutionarily related to the target using target sequence
and threading approaches; (B) Filtering the sub-set of holo
PDB structures using the target structure (experimental or
modeled) and structure comparison methods; (C) Select-
ing pockets and ligands from the filtered sub-set for bind-
ing site and virtual screening predictions.
FINDSITEfilt [12] employs a heuristic structure-pocket
alignment procedure and a sequence dependent scoring
Figure 2 Flowchart of FINDSITEcomb.
Figure 3 Flowchart of two FINDSITE-based component approaches (A) FINDSITEfilt (B) FINDSITEX.
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BLOSUM62 a; bð Þ; ð1Þ
where BLOSUM62(a,b) is the BLOSUM62 substitution
matrix [54]. Templates are ranked by their SP-scores and
the ligands corresponding to the top 100 templates are se-
lected as template ligands for ligand virtual screening.
FINDSITEX for ligand virtual screening using experimental
binding data without bound structures
FINDSITEfilt’s performance relies on the existence of a
sufficient number of holo PDB structures homologous to
the target. This is not true for most membrane proteins
where even apo structures (structures without bound li-
gands) are rare. Thus, for some of the most interesting
drug targets, such as the G-Protein Coupled Receptors
(GPCRs) and ion-channels, FINDSITEfilt has limited per-
formance. The FINDSITEX approach [53] was developed
to overcome the shortcomings of FINDSITEfilt on these
kinds of targets. The flowchart of FINDSITEX is shown in
Figure 3(B). FINDSITEX utilizes experimental binding
data without ligand bound experimental structures. To
use the benefits from structure comparison, structures of
proteins in experimental ligand binding database are mod-
eled. FINDSITEX uses the fast version of the structure
modeling approach TASSERVMT [55] (TASSERVMT-lite
[53]) to create a virtual library of protein-ligand structures
analogous to the PDB holo structures but without experi-
mentally solved protein-ligand complex structures. Since
there is no reliable pocket information for the virtual holo
structure, whole structure comparison of the target to the
templates (in the virtual holo structures) using fr-TM-
align [56] is used. To reduce false positives, especially for
targets like GPCRs where almost all structures are similar
(TM-score > 0.4), a sequence dependent score similar to
the SP-score in Eq. (1) over the fr-TM-aligned residues is
used instead of the TM-score. The ligands of the top
ranked templates are used as template ligands for searching
against compound library. To identify template-ligand
pairs, the DrugBank drug-target relational database [57]
and the ChEMBL bioactivity database [58] are used.
FINDSITEcomb for ligand virtual screening
FINDSITEcomb is the combination of FINDSITEfilt that
uses holo PDB structures as templates and FINDSITEX
that utilizes two independent ligand binding databases.
For a given target and compound library, if there is no tar-
get structure input, TASSERVMT-lite [53] models the
structure. Then, three independent virtual ligand screen-
ing runs are conducted: (a) FINDSITEfilt using the holo
PDB structure library; (b) FINDSITEX using the DrugBankvirtual holo structure library; and (c) FINDSITEX using
the ChEMBL virtual holo structure library. For each vir-
tual screening library, the following score is used to meas-





TC Ll; Llibð Þ
Nlg
þ 1−wð Þ max
l∈ 1;…;Nlgð Þ
TC Ll; Llibð Þð Þ; ð2Þ
where TC stands for the Tanimoto Coefficient [59], Nlg
is the number of template ligands from the putative evo-
lutionarily related proteins; Ll and Llib stand for the tem-
plate ligand and the ligand in the compound library,
respectively; w is a weight parameter. The first term is
the average TC [11]. The second term is the maximal
TC between a given compound and all the template li-
gands. Here, we empirically choose w = 0.1 to give more
weight to the second term so that when the template li-
gands are true ligands of the target, they will be favored.
For a given compound, three independent virtual screen-
ings give three mTC scores and the maximal score is
used for the combined ranking.
In this study, to experimentally validate FINDSITEcomb
under non-trivial conditions, i.e. there are no close hom-
ologous templates to the target, we have excluded all
templates having sequence identity > 30% to given target
in the PDB holo structures, DrugBank targets and
ChEMBL targets.
Comparison of FINDSITEcomb to traditional docking-based
methods
We previously conducted a benchmarking test of
FINDSITEcomb on the DUD set (A Directory of Useful
Decoys set [60]) and compared our results to the state-
of-the-art docking-based methods for ligand virtual
screening. The DUD set is designed to help test docking
algorithms by providing challenging decoys. It has a total
of 2,950 active compounds and a total of 40 protein tar-
gets. For each active, there are 36 decoys with similar
physical properties (e.g. molecular weight, calculated
LogP) but dissimilar topology. Two freely available trad-
itional docking methods AUTODOCK Vina [61] (http://
vina.scripps.edu/) and DOCK 6 [62] (http://dock.compbio.
ucsf.edu/DOCK_6/) were compared to FINDSITEcomb.
AUTODOCK Vina was tested on the DUD set and shown
to be a strong competitor against some commercially dis-
tributed docking programs (http://docking.utmb.edu/
dudresults/). DOCK 6 is an update of the DOCK 4 pro-
gram [62]. These two methods represent state-of-the-art
traditional docking-based approaches that are computa-
tionally expensive, but do not require a known set of
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similarity-based approaches. FINDSITEcomb also does not
require a known set of binders for the target, but is an
order of magnitude faster than docking methods. Most im-
portantly, FINDSITEcomb does not require a high-
resolution experimental structure of the target. Thus, it is
applicable for screening both large compound library and
for genomic scale targets.
The performance of a given approach for virtual
screening is evaluated by the Enrichment Factor (EF)
within the top x fraction (or 100x%) of the screened li-
brary compounds defined as:
EFx ¼ Number of true positives within top 100x%Total number of true positives  x :
ð3Þ
A true positive is defined as an experimentally known
binding ligand/drug or one that has a TC = 1 to an ex-
perimentally validated binding ligand/drug. For x = 0.01,
EF0.01 ranges from 0 to 100 (100 means that all true pos-
itives are within the top 1% of the compound library).
Another evaluation quantity employed here is the AUAC
(area under accumulative curve of the fraction of true
positives versus the fraction of the screened library).
The performance of the three approaches on the DUD
set using experimental target structures is shown in
Table 3. FINDSITEcomb shows about 3 times the EF0.01
of AUTODOCK Vina or DOCK 6 for the top 1% se-
lected compounds, with an EF0.01 of 13.4 versus 4.80
and 3.72, respectively. FINDSITEcomb has significantly
better overall performance in terms of its AUAC (0.774
vs. 0.586 and 0.426). Although we do not have direct ac-
cess to some of the commercially available approaches
compared in Ref. [63], we note that FINDSITEcomb has a
better AUAC than the best performing GLIDE (v4.5)
[64,65] (mean AUAC = 0.72) and all other compared
methods: DOCK 6 (mean AUAC = 0.55), FlexX [66]
(mean AUAC = 0.61), ICM [67,68] (mean AUAC =
0.63), PhDOCK [69,70] (mean AUAC = 0.59) and Sur-
flex [71-73] (mean AUAC = 0.66) [63]. The results ofTable 3 Performance of methods on the 40 protein DUD









FINDSITEcomb 13.4 6.56 4.37 0.774
AUTODOCK Vina 4.80 3.01 2.40 0.586
(5.3×10-4)a (9.4×10-4) (7.7×10-4) (3.0×10-7)
DOCK 6 3.72 1.79 1.24 0.426
(1.5×10-4) (1.8×10-5) (9.9×10-7) (1.3×10-12)
aNumbers in parentheses are two-sided p-values of Student-t test between
FINDSITEcomb and docking methods.DOCK 6 in Ref [63] are better than that in Table 3 is
due to the use of flexible docking and expertise in input
preparation in Ref. [63], whereas here we employed de-
fault input and rigid docking.
We next examined the effect of target structure quality
on the performance of methods. In Table 4, we show the
enrichment factors EF0.01 and EF0.1 of different methods
using experimental and modeled target structures for a
subset of 30 targets from DUD set. The other 10 targets
are not included because the modeled structures have
extended long tails (not compact) and their dimensions
are too large for docking methods. The results of
FINDSITEcomb change very little when modeled struc-
tures as compared to experimental structures are used.
This is not the case for either DOCK6 or AUTODOCK
whose performance significantly deteriorates.Large scale testing of FINDSITEcomb on generic drug
targets
Since FINDSITEcomb is much faster than traditional
docking approaches and can use modeled as well as ex-
perimental structures, we can perform large-scale testing
on drug targets (some of which lack experimental struc-
tures). This kind of test is not feasible for traditional
docking methods. We tested FINDSITEcomb on a set of
3,576 DrugBank [57] targets that we can confidently
model using TASSERVMT-lite [53]. We use modeled tar-
get structures even for those targets that have experi-
mental PDB structures. Drugs of all the 3,576 targets are
buried in a background of representative compounds
that are culled to TC < 0.7 to each other from the
ZINC8 library [74]. The total number of screened com-
pounds for each target is 74,378 (6,507 drugs +67,871
ZINC8 compounds).
The test results are shown in Table 5. FINDSITEcomb
achieves an average enrichment factor of 52 for the top 1%
of (viz. ranked within the top 744) selected compounds;
moreover, about 65% of the targets have an EF0.01 > 1
(EF = 1.0 is by random selection). Thus, on average about
half of the true drugs of typical target will show up within
top 1% of the screened compounds. FINDSITEcomb will be
helpful in enriching true binders for 65% of the targets in a
typical genome sequence. We note that FINDSITEcomb is
better than any of its individual components. The majorTable 4 Comparison of methods for the 30 protein DUD













FINDSITEcomb 14.1 13.3 4.54 4.53
AUTODOCK Vina 5.45 2.39 2.48 1.40
DOCK 6 3.82 3.05 1.29 0.87
Table 5 Performance of FINDSITE methods for 3,576 drug
targets
Method (binding database) Average EF0.01 # (%) of targets
having EF0.01 > 1
FINDSITE (PDB) 31.7 1526 (43%)
FINDSITEX (DrugBank) 36.6 1714 (48%)
FINDSITEX (ChEMBL) 9.5 566 (16%)
FINDSITEfilt (PDB) 46.0 2080 (58%)
FINDSITEcomb 52.1 2333 (65%)
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holo PDB structure templates.
Experimental validation of FINDSITEcomb
For the experimental blind validation of this work, a
compound library with molecules from the National
Cancer Institute (NCI) and ZINC8 [74] (TC < 0.7) as
background was used. The open chemical repository
maintained by the Developmental Therapeutics Program
(DTP) at NCI/NIH is a comprehensive set of small mol-
ecules consisting of compounds from the diversity set,
mechanistic set, natural product set and approved oncol-
ogy drug set. Compounds constituting the diversity set
were derived from a parent library of ~140,000 com-
pounds based on the following criteria: (1) Distinctness
of the molecule, its pharmacophores and its conform-
ational isomers, (2) Rigidity (5 or fewer rotatable bonds),
(3) Planarity and (4) Pharmacologically desirable fea-
tures. Compounds constituting the mechanistic set were
selected from a seed library of 37,836 compounds tested
on the NCI human tumor 60 cell line screens and repre-
sent compounds that show a broad range of growth in-
hibition. Compounds in the natural product set were
selected from 140,000 compounds in the DTP open re-
pository collection based on (a) origin, (b) purity, (c)
structural diversity (differential scaffolds structures with
varied functional groups), and (d) availability. The com-
pounds in the approved oncology drug set consist of
current FDA-approved drugs.
The reason for using NCI molecules was that they are
easy to obtain. The NCI molecules are downloaded from
NCI (http://dtp.nci.nih.gov/branches/dscb/repo_open.html)
and consist of 1597 molecules from the Diversity Set III, 97
from the Approved Oncology Drugs Set IV, and 118 from
the Natural Product Set II (total 1812 NCI molecules). The
important fact is that no a priori target-compound binding
information is used in both virtual screening and experi-
mental validation. Together with the ZINC8 background, a
total of 69683 molecules are screened by FINDSITEcomb.
NCI molecules ranked within the top 1% (i.e. higher
than ~700th) for each target are subsequently consid-
ered for thermal shift experimental validation.Acquisition and quantification of thermal shift assays
High throughput thermal shift assays were carried out
following established guidelines (Additional file 1: Table
S1) [13,75]. Protein melting curves were obtained from
samples aliquoted in 96-well plates using a RealPlex
quantitative PCR instrument from Eppendorf (Eppendorf,
NY, USA), with Sypro orange dye from Invitrogen as
the fluorescent probe. A uniform final concentration of
5 X (supplied as a 5000 X stock solution) was used in
all experiments. The dye was excited at 465 nm and
emission recorded at 580 nm using the instrument’s fil-
ters. A heating ramp of 1°C/min from 25°C to 74°C was
used, and one data point acquired for each degree in-
crement. For standardization, different buffers and pH
were checked. Thereafter, 100 mM HEPES pH 7.3 and
150 mM NaCl were used in all unfolding experiments.
The volume of each reaction was 20 μl, and appropriate
dye and protein controls were included. All experi-
ments were done with a minimum of two replicates,
with the mean value considered for further analysis.
Several drugs/small molecules interact with Sypro or-
ange and lead to aberrant signal enhancements. An
additional control to rule out drug-dye interaction was
carried out with all the constituents kept constant except
for the protein of interest. The protein/protein-drug
curves were reported after subtracting the respective
dye alone/drug-dye curves.
Each melting curve was assigned a quality score (Q), the
ratio of the melting-associated increase in fluorescence
(ΔFmelt) to the total fluorescence range (ΔFtotal). Q = 1 is a
high-quality curve, while Q = 0 indicates no thermal tran-
sition [75]. Though an arbitrary Q value cutoff was not ap-
plied to judge curve quality, the curves were manually
curated with Q values reported. A substantial fraction of
ligands tested against the various proteins displayed no
thermal transitions, Q = 0, or showed multi-step unfolding
behavior. These were ignored (see Table 1).
Data analysis
Subsequent to standardization, (see SI Methods), the val-
idity of the top 1% of FINDSITEcomb’s predictions on the
test set of eight diverse proteins was examined. To be
conservative, we focused only on those protein/ligand
pairs showing single sigmoidal thermal transition curves.
The fit to Boltzmann’s equation (Eq. 1) was employed
to estimate the melting temperature from the observed
intensity, I.
I ¼ Imin þ Imax−Imin½ 
1þ e Tm−Tað Þ
ð4Þ
Imin and Imax are the minimum and maximum inten-
sities; a denotes the slope of the curve at the transition
midpoint temperate, Tm [13]. To estimate thermodynamic
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analyses were done [77]. To estimate the approximate
ligand-binding affinity at Tm, Eq. (2) from reference [78]
was used with slight modifications; ΔCp is ignored.









KL(Tm) is the ligand association constant and [L] is the
free ligand concentration at Tm ([LTm] ~ [L]total, when
[L]total > > the total concentration of protein. KD is the
inverse of KL(Tm).
To eliminate the possibility of thermal shifts arising
because organic molecules form colloidal aggregates
[79], the complete NCI set was compared to the data-
base of known aggregators maintained at http://advisor.
bkslab.org/search/. Since the thermal shift assay is in-
compatible with the presence of detergents, (the method
of choice to eliminate aggregation-based thermal shifts),
we limited ourselves to estimate chemical similarity to
known aggregators. At a stringent TC cutoff of 0.9, none
of the molecules reported as possessing either binding
or antimicrobial/cytotoxic activities are similar to known
aggregators.
Antimicrobial and cytotoxic assays on cancer cell lines
Antimicrobial and anti-cancer tests were performed as
in [80]. DHFR binders were tested on E. coli DH5α
[positive control: Nitrofurantion (10 mg/ml in DMSO,
negative control: DMSO], multi-drug resistant E. coli
SMS-3-4 (ATCC BAA-1743) (MDREC) [positive control:
Nitrofurantion (10 mg/ml in DMSO), negative control:
DMSO], methicillin-resistant S. aureus (ATCC 33591)
(MRSA) [positive control: Vancomycin (10 mg/ml in
DMSO), negative control: DMSO], vancomycin-resistant
E. faecium (ATCC700221) (VREF) [positive control:
Chloramphenicol (10 mg/ml in DMSO), negative con-
trol: DMSO], and colon carcinoma cells HCT-116 [posi-
tive control: etoposide (20 μg/ml in DMSO), negative
control: DMSO]. Phosphatase (1000001 and 1000006)
binders and tryptophanyl tRNA synthetase binders were
tested on the colon carcinoma cell line HCT-116.
Additional file
Additional file 1: Detailed FINDSITEcomb VLS results, Thermal shift
assay standardization: methods and results, HTS protocol table,
detailed results on the thermal shift assay and biological activity
assay for the eight protein in tabular form, discussion on the
differences between 1000001 and 1000006 VLS and experimental
overlap and figure depicting the diversity of compounds picked up
by the current methodology.
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